An accessibility startup details how they delivered The Oscars Project, which will bring ASL interpretation to all 10 Best ...

The president originally responded with a 10% global tariff after Friday’s ruling — only to raise it to 15% one day later. For imports from many countries, it is an ...

After a decade, the GDP series is undergoing a revision. Some of the proposed changes will make for a more accurate reading of the economy but the shortcomings of the deflator will remain ...

The Voya Securitized Credit Fund delivered attractive total and excess returns, but underperformed the Bloomberg US ...

For years, Russ Arjal, MD, a gastroenterologist and co-founder and chief medical officer of WovenX, watched the same pattern repeat itself in gastroenterology. The specialists were skilled. The care ...

Good afternoon, everyone, and welcome to Solvay's Fourth Quarter and Full Year 2025 Earnings Call. I'm Geoffroy d'Oultremont, Head of Investor Relations. And with me today are our CEO, Philippe Kehren ...

For Illinois, Trump's strong-arm approach has meant regular threats to a range of federal funding streams, which add up to at ...

Phase III study will be "sufficient and pivotal for registration in the U.S." Kiniksa Pharmaceuticals ( KNSA +1.56%) ...

BY BAYO AJETUMOBI The latest chapter of the long-running dispute in the Nigerian advertising industry was written ...

Fellow shareholders, Axon completed another record year in pursuit of our mission to protect life. Revenue grew 33% year over year, marking our fourth consecutive year of annual g ...

On Friday, the Supreme Court struck down the centerpiece of President Trump’s second-term tariff agenda. But the ruling did ...

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2025 Earnings Call Transcript February 24, 2026 Kiniksa Pharmaceuticals, Ltd.